“Apparently FDA have a lot of fate in the possibilities of gene-therapy” Interview with Jan Nilsson

Sep 4, 2018

“During 2018 CombiGene together with CGT Catapult will drive the process development of our pharmacutical canidate CG01 in order to in 2019 start the regulatory obligatory biodistribution and toxocologystudies. — Jan Nilsson, CEO CombiGene

Read the entire interview at Boistock with Jan Nilsson, CEO at CombiGene here: (Only in swedish)

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.


Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook